Introduction
============

Currently, kidney transplantation (KT) is the treatment of choice for patients with end-stage renal failure. The transplantation surgery is commonly performed under general anesthesia using a volatile anesthetic agent. However, sevoflurane - a commonly used volatile anesthetic - has the potential to adversely affect the function of a grafted kidney as well as the outcome of KT because an inorganic fluoride ion produced during sevoflurane metabolism is related to methoxyflurane-induced nephrotoxicity \[[@B1]\]. Furthermore, compound A - another product of sevoflurane metabolism in the presence of carbon dioxide - can affect the breathing circuit and has been shown to cause renal damage in animals \[[@B2]\]. Although it has been generally accepted that sevoflurane can be used without concern for nephrotoxicity \[[@B3]\], this is the subject of a debate that is still ongoing because of a number of reports of sevoflurane-induced nephrotoxicity in humans \[[@B4]-[@B8]\].

Furthermore, grafted kidneys are very sensitive during transplantation. Various factors, such as ischemia-reperfusion (IR) injury, can cause early renal dysfunction, which can increase the risk of acute rejection episodes and graft failure \[[@B9],[@B10]\]. Reports regarding the effects of sevoflurane on transplanted kidneys are limited, although there have been several suggestions of increased risk of renal damage while using sevoflurane \[[@B11]\].

Therefore, the objective of this retrospective study was to determine whether there are any differences in grafted kidney function in recipients or in the outcomes of KT when donors and recipients were anesthetized with sevoflurane compared to desflurane.

Materials and Methods
=====================

After approval from the Institutional Review Board, we performed a retrospective review of the electronic medical records at our institution, of patients 20 years or older who had received a kidney transplant from a living donor from January 2006 to June 2009. We included pairs of donors and recipients where the recipient had been anesthetized with the same volatile anesthetics as the donor. Among the selected pairs, those with incomplete medical records or unstable hemodynamic events during the transplantation operation were excluded from the study ([Fig. 1](#F1){ref-type="fig"}). We defined an unstable hemodynamic event as documentation of an intra-operative mean arterial pressure (MAP) of more than 30% below baseline or a blood oxygen saturation of less than 95%. We ultimately identified 149 eligible pairs for this study. The pairs were divided into three groups: pairs anesthetized with sevoflurane (n = 73, Sevo group), pairs anesthetized with desflurane (n = 71, Des group), and pairs anaesthetized with isoflurane (n = 5). We excluded the pairs anesthetized with isoflurane because of the small sample size.

All donors and recipients were administered general anesthesia with mechanical ventilation. Induction of anesthesia was performed with an intravenous anesthetic (propofol or thiopental), an opioid (fentanyl or remifentanil), and a muscle relaxant (atracurium, vecuronium, or rocuronium). A balanced anesthetic technique was performed for maintenance anesthesia using a volatile anesthetic (sevoflurane or desflurane), an opioid (intermittent intravenous fentanyl or an intravenous infusion of remifentanil), and a muscle relaxant (intravenous infusion of atracurium). Soda lime was used as a carbon dioxide absorbent in all patients.

An immunosuppressed condition was achieved using the following regimen in both groups: induction of immunosuppression with baciliximab and methylprednisolone and maintenance with calcineurin inhibitor (cyclosporine or tacrolimus \[FK 506\]), methylprednisolone, and an antimetabolite (mycophenolic acid or mizoribine).

We analyzed the factors affecting grafted kidney function and compared them between the Sevo group and the Des group. These factors included the following: age, sex, weight, height, co-morbid disease, preoperative serum level of blood urea nitrogen (BUN) and creatinine (Cr), intra-operative intake/output, total ischemic time, number of matched human leukocyte antigens (HLA)-A, B, and HLA-DR, and type of calcineurin inhibitor. Function of the grafted kidney was estimated by the serum level of BUN, Cr, and estimated glomerular filtration rate (eGFR) on postoperative day (POD) 1, 2, 4, and 7, at discharge, and at 12 months after transplantation. The eGFR was calculated using the MDRD (modification of diet in renal disease) equation. We also investigated the frequency of delayed graft function (DGF), treated acute rejection episodes (ARE), and graft loss within one year of transplantation. DGF was indicated in graft recipients who underwent dialysis during the first week after transplantation. ARE included both biopsy-proven acute rejection and clinically suspected acute rejection. We defined a graft loss as the initiation of long-term dialysis therapy after transplantation.

Data were analyzed using PASW Statistics 18.0 (SPSS Inc., Chicago, IL, USA). We used an independent t-test to compare the grafted kidney function between the two groups. We tested noninferiority for serum creatinine at discharge and 1 yr after KT. To test non-inferiority or equivalence, a margin of equivalence (the largest difference that is not of practical significance) must first be defined. Because the increase of 0.3 mg/dl of serum creatinine is attributed to \'risk\' criteria according to the definition of acute kidney injury \[[@B12]\], a maximum difference of 0.3 mg/dl in the serum creatinine was considered as equivalence. The Fisher\'s exact test was used to compare the frequency of DGF between the two groups. A P value \< 0.05 was considered statistically significant.

Results
=======

There were no significant differences in donor and recipient demographics or intraoperative data between the Sevo group and the Des group ([Table 1](#T1){ref-type="table"}).

Grafted kidney function during the immediate postoperative period was comparable between the two groups ([Fig. 2](#F2){ref-type="fig"}). There were 2 patients with DGF in the Sevo group and 1 patient with DGF in the Des group; this difference was not statistically significant.

The duration of hospitalization and grafted kidney function at the time of discharge were comparable between the groups. The short-term outcomes of transplantation and transplanted renal function at 1 year after renal transplantation were also comparable between the two groups, as both groups showed no significant differences in the occurrence of ARE or graft loss for 1 year after transplantation ([Table 2](#T2){ref-type="table"}). The mean difference in serum creatinine and their 95% confidence interval (CI) are presented in [Table 3](#T3){ref-type="table"}. At the time of discharge, the 95% CI (Sevo group minus Des group) fell within the margin of equivalence, and therefore the grafted kidney function on the discharge day between the groups was considered as equivalent. However, because the 95% CI at the time of 1 year after surgery included-0.3, the grafted kidney function of the Sevo group at that time was considered as non-inferior, rather than equivalent, to that of the Des group.

Discussion
==========

The results of this retrospective study provide no direct evidence that sevoflurane has deleterious effects on grafted kidney function compared to desflurane because there were no differences in postoperative serum creatinine, BUN, estimated GFR, or urine output between the sevoflurane and desflurane groups. Also, the outcomes of renal transplantation surgery at 1 year after surgery were comparable between the Sevo group and the Des group. Finally, we can conclude that sevoflurane does not adversely affect grafted renal function at the time of discharge and at 1 year after transplantation because the differences in creatinine between the two groups (Sevo group minus Des group) were less than 0.3 mg/dl, which is the margin of equivalence.

A previous report has already demonstrated that sevoflurane has no detectable effect on the outcome of kidney transplantation \[[@B13]\]. This report assessed renal function in recipients anesthetized with sevoflurane compared to isoflurane, irrespective of the anesthetics used for the donors. However, in animal studies and a in handful of human studies, renal damage related to sevoflurane has been reported to be correlated with the exposure duration and the concentration of serum inorganic fluoride ion and inspired compound A \[[@B3]\]. As such, the transplanted kidneys may have been exposed to fluoride and compound A if the donors were anesthetized with sevoflurane. Therefore, if sevoflurane has an adverse effect on renal graft function, it should be more pronounced in grafted kidneys in which both the donor and recipient were anesthetized with sevoflurane.

Inorganic fluoride was suggested to be nephrotoxic in studies using methoxyflurane \[[@B14],[@B15]\]. Although Higuchi et al. reported that elevated serum fluoride concentrations (\> 50 µmol/L) secondary to sevoflurane may contribute to postoperative renal impairment \[[@B4]\], there was no such relationship between the serum fluoride concentrations and nephrotoxicity in the majority of other studies that used sevoflurane \[[@B3],[@B11]\]. In contrast, compound A has been reported to be correlated with renal toxicity in several studies. In human volunteers, compound A, at concentrations ranging from 150 to 342 ppm-h after sevoflurane administration, induced transient abnormalities in urine biochemical markers \[[@B4],[@B5]\]. Furthermore, compound A exposures of 240 ppm-h from sevoflurane resulted in albuminuria and increased excretion of α-glutathione-S-transferase (a biochemical marker in urine) \[[@B7]\]. Additionally, surgical patients with low-flow sevoflurane anesthesia were exposed to compound A at 214 ppm-h and exhibited mild, transient proteinuria and increased excretion of N-acetyl-β-D-glucosaminidase (a lysosomal enzyme located in the proximal renal tubule) \[[@B8]\]. Nevertheless, no studies have ever reported nephrotoxicity induced by sevoflurane that could be detected by routine clinical tests of renal function (serum BUN, Cr, or creatinine clearance). This suggests that nephrotoxicity secondary to sevoflurane may be too mild and transient to affect renal function. Additionally, there were also no detectable influences on renal function secondary to sevoflurane in patients with stable renal insufficiency \[[@B16],[@B17]\]. Based on these studies, since 2006, sevoflurane has been administered to patients undergoing renal transplantation in our institution. However, grafted kidneys could be damaged by various factors during and even after renal transplantation. IR injury during the transplantation procedure may contribute to delayed graft function. This could subsequently increase allograft immunogenicity and increase the risk of acute rejection episodes, which could ultimately result in graft failure \[[@B9],[@B10]\]. Furthermore, immunosuppressants such as cyclosporine or tacrolimus used after renal transplantation can cause nephrotoxicity, although they do result in decreased acute rejection rates and improved short-term outcomes \[[@B18]\]. These conditions in which the kidney grafts can be damaged during and after surgery are so unique that they are not observed in other types of surgeries. Renal damage secondary to sevoflurane may occur under these conditions, although nephrotoxicity attributable to sevoflurane is clinically insignificant in patients with stable renal insufficiency. Therefore, we need to confirm whether sevoflurane can safely be used in patients undergoing renal transplantation.

There is yet another issue regarding sevoflurane and renal function in renal transplantation. There have been several reports suggesting the protective effects of volatile anesthetics against renal IR injury \[[@B19]-[@B21]\]. These protective effects have not been definitively established; however, these reports suggest that volatile anesthetics may actually have a positive effect on the human kidney. In clinical practice, potential evidence for renal protection by volatile anesthetics was illustrated in a recent study by Julier et al. \[[@B22]\]. Their study showed that sevoflurane pretreatment before cardiopulmonary bypass for coronary artery bypass grafting surgery markedly improved postoperative GFR as determined by the plasma concentration of cystatin C. Therefore, sevoflurane may confer positive effects on renal graft function by reducing IR injury.

There are several limitations to this study. First, we could not assess the levels of inorganic fluoride and compound A. Therefore, we could not confirm whether these affect the grafted kidney function. In addition, we evaluated the function of the grafted kidney, not the severity of damage related to sevoflurane. To clarify the nephrotoxicity of sevoflurane, we need to assess the renal injury using a novel biomarker such as neutrophil gelatinase-associated lipocalin (NGAL). NGAL has emerged as a new diagnostic tool for acute kidney injury \[[@B23]\]. In kidney transplant patients, NGAL not only predicts DGF \[[@B24],[@B25]\], but also correlates with grafted kidney function \[[@B26],[@B27]\]. Second, we were unable to confirm whether or not sevoflurane had an effect on grafted renal function in the immediate posttransplantation period. However, we showed that there was no deterioration in grafted renal function in the Sevo group at the time of discharge and 1 year after renal transplantation. Therefore, we believe that sevoflurane can safely be used in patients undergoing renal transplantation.

In conclusion, sevoflurane has no adverse effects on renal graft function or on the short-term outcome of renal transplantation compared to desflurane.

![Flowchart of data acquisition. Of the patients who underwent kidney transplantation from a living donor from January 2006 to June 2009, this study included donor-recipient pairs in which the recipient had been anesthetized with the same volatile anesthetic as the donor. We excluded the pairs in which isoflurane was used because of the small sample size. Finally, the enrolled pairs were divided into groups, the sevoflurane group (n = 73, Sevo group) and the desflurane group (n = 71, Des group). IMR, incomplete medical record; UHE, unstable hemodynamic event during transplantation.](kjae-62-529-g001){#F1}

![Transplanted renal function in the immediate postoperative period. Changes in serum blood urea nitrogen (BUN), creatinine (Cr) level, estimated glomerular filtration rate (eGFR), and urine output in the Des group (□) and in the Sevo group (•) during the immediate postoperative period. The changes in the serum concentrations of BUN, Cr, eGFR, and urine output of the recipients during the immediate postoperative period were comparable between the two groups.](kjae-62-529-g002){#F2}
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Demographic and Intra-operative Data of the Patients
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Data are mean ± standard deviation, median (range), or number of patients (percent). HLA: human leukocyte antigen, eGFR: estimated glomerular filtration rate, PRA: panel reactive antibodies.
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Grafted Kidney Function and Outcomes at 1 Year after Transplantation
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All data are mean ± standard deviation, number of episodes, or patients (percent). DGF: delayed graft function, eGFR: estimated glomerular filtration rate, ARE: acute rejection episode.
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Mean Differences and Their 95% Confidence Intervals for the Serum Creatinine (Sevo Group Minus Des Group) at the Time of Discharge and 1 Year after Surgery
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